StockNews.com assumed coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a research report report published on Friday morning. The brokerage issued a sell rating on the biotechnology company’s stock. MRTX has been the subject of a number of other reports. SVB Leerink reiterated a market perform rating and issued a $58.00 price […]
Rhenman & Partners Asset Management AB grew its stake in Mirati Therapeutics, Inc. (NASDAQ:MRTX – Free Report) by 25.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 175,000 shares of the biotechnology company’s stock after purchasing an additional 35,000 shares during […]
Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Free Report) have earned an average recommendation of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Eleven analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price […]
StockNews.com began coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a research note released on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock. Several other analysts have also recently commented on MRTX. Piper Sandler cut shares of Mirati Therapeutics from an overweight rating to a neutral rating and […]
Stock analysts at StockNews.com began coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Get Free Report) in a report released on Monday. The firm set a “sell” rating on the biotechnology company’s stock. MRTX has been the topic of a number of other reports. Stifel Nicolaus reaffirmed a “hold” rating and issued a $59.00 price […]